Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.

Click here now to get your free 'Protect Your Wealth' Guide.

Eric K. Rowinsky net worth and biography

Eric Rowinsky Biography and Net Worth

Director of Biogen

Eric K. Rowinsky, M.D., joined our Board of Directors in 2010. Dr. Rowinsky is a member of our Corporate Governance Committee and our Compensation and Management Development Committee. Dr. Rowinsky has served as Executive Chairman of Inspirna since December 2015. From January 2012 to November 2015 Dr. Rowinsky was the Head of Research and Development and Chief Medical Officer of Stemline Therapeutics, Inc., a biotechnology company focusing on the discovery and development of therapeutics targeting cancer stem cells. Dr. Rowinsky is an Adjunct Professor of Medicine at New York University and has been an independent consultant since January 2010. Prior to that, he was the Chief Medical Officer of Primrose Therapeutics, Inc., a start-up biotechnology company focusing on the development of therapeutics for polycystic kidney disease, from August 2010 until its acquisition in September 2011. From 2005 to December 2009 he served as the Chief Medical Officer and Executive Vice President of ImClone Systems Incorporated, a life sciences company. From 1996 to 2004 Dr. Rowinsky held several positions at the Cancer Therapy & Research Center’s Institute for Drug Development, including Director of the Institute and Director of Clinical Research. During that time, he held the SBC Endowed Chair for Early Drug Development and was Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. From 1988 to 1996 Dr. Rowinsky was an associate professor of oncology at the Johns Hopkins School of Medicine and on the staff of the Johns Hopkins Hospital.

Dr. Rowinsky is also a member of the Boards of Directors of Fortress Biotech Inc., Purple Biotech Ltd. (formerly Kitov Pharma Ltd.) and Verastem, Inc., all of which are biopharmaceutical companies.

What is Eric K. Rowinsky's net worth?: The estimated net worth of Eric K. Rowinsky is at least $3.24 million as of February 15th, 2024. Dr. Rowinsky owns 20,629 shares of Biogen stock worth more than $3,241,641 as of November 19th. This net worth approximation does not reflect any other assets that Dr. Rowinsky may own. Learn More about Eric K. Rowinsky's net worth.
How do I contact Eric K. Rowinsky?: The corporate mailing address for Dr. Rowinsky and other Biogen executives is 225 BINNEY STREET, CAMBRIDGE MA, 02142. Biogen can also be reached via phone at (617) 679-2000 and via email at [email protected]. Learn More on Eric K. Rowinsky's contact information.
Has Eric K. Rowinsky been buying or selling shares of Biogen?: Eric K. Rowinsky has not been actively trading shares of Biogen over the course of the past ninety days. Most recently, on Thursday, February 15th, Eric K. Rowinsky bought 455 shares of Biogen stock. The stock was acquired at an average cost of $222.54 per share, with a total value of $101,255.70. Following the completion of the transaction, the director now directly owns 20,629 shares of the company's stock, valued at $4,590,777.66. Learn More on Eric K. Rowinsky's trading history.
Who are Biogen's active insiders?: Biogen's insider roster includes Susan Alexander (EVP), Brian Posner (Director), Eric Rowinsky (Director), Alfred Sandrock (insider), Priya Singhal (Insider), and Michel Vounatsos (CEO). Learn More on Biogen's active insiders.
Are insiders buying or selling shares of Biogen?: During the last twelve months, Biogen insiders bought shares 1 times. They purchased a total of 455 shares worth more than $101,255.70. During the last twelve months, insiders at the biotechnology company sold shares 6 times. They sold a total of 1,423 shares worth more than $317,328.92. The most recent insider tranaction occured on September, 3rd when insider Priya Singhal sold 431 shares worth more than $88,018.82. Insiders at Biogen own 0.2% of the company. Learn More about insider trades at Biogen.
Information on this page was last updated on 9/3/2024.

Eric K. Rowinsky Insider Trading History at Biogen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/15/2024	Buy	455	$222.54	$101,255.70	20,629
3/20/2015	Sell	11,666	$475.00	$5,541,350.00
3/19/2015	Sell	2,332	$436.14	$1,017,078.48
3/17/2015	Sell	4,665	$425.45	$1,984,724.25

Eric K. Rowinsky Buying and Selling Activity at Biogen

Biogen Company Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $157.14

$157.14

50 Day Range

MA: $185.16

$157.94

$201.44

2 Week Range

Now: $157.14

$157.14

$268.30

Volume

1,740 shs

Average Volume

1,166,407 shs

Market Capitalization

$22.90 billion

P/E Ratio

14.20

Dividend Yield

N/A

Beta

N/A

Central Bank Abandons USD

From True Gold Republic | Ad